Loading…
CODEINE LINCTUS BP is a brand name for Codeine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Codeine is indicated in adults for relief of the symptoms of dry or irritating coughs.
Verbatim from this product's MHRA label. Tap a section to expand.
4). Oral.
Adults:
One 5ml spoonful.
Elderly:
Use with caution, a reduced dose can be recommended by a doctor.
Paediatric population:
Codeine should not be used for the treatment of children under the age of 18 years.
Dosage schedule:
The dose may be repeated after four hours if required, but not more than 4 doses in any 24 hours.
The following undesirable effects have been reported following use of codeine phosphate or opioid analgesics and may arise following use of Codeine Linctus. The frequency of adverse effects cannot be estimated from available data. 4).
Nervous system disorders: dizziness, drowsiness, seizures, addiction, tolerance, dependence, headache, vertigo, malaise, sleep disturbances. Eye disorders: miosis, visual disturbances. Cardiac disorders: palpitations, bradychardia, tachycardia.
Vascular disorders: postural hypotension, hypothermia, facial flushing, oedema. Respiratory, thoracic and mediastinal disorders: respiratory depression. Gastrointestinal disorders: nausea, vomiting, constipation, abdominal pain, anorexia, pancreatitis, dry mouth.
Hepatobiliary disorders: biliary spasm. Skin and subcutaneous tissue disorders: rashes, urticaria, pruritus, sweating. Musculoskeletal and connective tissue disorders: muscle fasciculation or rigidity. Renal and urinary disorders: difficulty with micturition, ureteric spasm or retention.
Reproductive system and breast disorders: decreased libido or potency. General disorders and administration site conditions: drug withdrawal syndrome (uncommon) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.
Suspected opiate abuse, known hypersensitivity to codeine or to any of the other ingredients. In cases of liver failure, respiratory depression, or patients at risk of paralytic ileus. In patients with raised intracranial pressure or head injury.
In patients for whom it is known they are CYP2D6 ultra-rapid metabolisers. During an acute asthmatic attack. Children under 18 years of age. 6) Special warnings and precautions for use Use with caution in patients with renal and hepatic impairment(but avoid if severe), patients suffering from asthma or other respiratory disorders, or patients with a history of asthma, hypotension, shock, myasthenia gravis, cardiac arrhythmias, acute abdomen, gallstones, prostatic hypertrophy, urethral stenosis, obstructive or inflammatory bowel disorders, diseases of the biliary tract, and convulsive disorders.
Administration of pethidine and possibly other opioid analgesics to patients taking a monoamine oxidase inhibitor (MAOI) has been associated with very severe and sometimes fatal reactions. If the use of codeine is considered essential then great care should be taken in patients taking MAOIs or within 14 days of stopping MAOIs.
5). Use with caution in the elderly, as codeine may induce faecal impaction, producing incontinence, spurious diarrhoea, abdominal pain and, rarely, colonic obstruction. Prolonged use could aggravate irritable bowel syndrome. A reduced dose is recommended in elderly or debilitated patients, in hepatic and renal impairment (but avoid if severe), in hypothyroidism, and in adrenocortical insufficiency.
Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence or in acute alcoholism.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Codeine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Codeine Linctus and other cough suppressants may cause sputum retention and this may be harmful in patients with chronic bronchitis and bronchiectasis. If symptoms persist consult your doctor. CYP2D6 metabolism Codeine is metabolised by the liver enzyme CYP2D6 into morphine, its active metabolite.
If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect will not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an extensive or ultra-rapid metaboliser there is an increased risk of developing side effects of opioid toxicity even at commonly prescribed doses.
General symptoms of opioid toxicity include nausea, vomiting, constipation, lack of appetite and somnolence. In severe cases this may include symptoms of circulatory and respiratory depression. These patients convert codeine into morphine rapidly resulting in higher than expected serum morphine levels.
9% Northern European 1%-2% Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Codeine Linctus contains Quinoline Yellow Solution Compound which contains Sunset Yellow (E110) and Quinoline Yellow (E104).
Sunset Yellow may cause allergic reactions.
Precautions/warnings to be declared on labels:
Do not exceed the stated dose. Keep out of the sight and reach of children. This product contains 4g of sucrose per dose. To be taken into account in people with diabetes. It also contains invert syrup. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
It contains a small amount of ethanol (alcohol), less than 100mg per 5ml. Drug dependence, tolerance and potential for abuse For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses.
, major depression). Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse. A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on- line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of relief as initially experienced. Patients may also supplement their treatment with additional medicines.
These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient. Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction. The clinical need for analgesic treatment should be reviewed regularly. Drug withdrawal syndrome Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with codeine phosphate.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and […]